Cargando…

Correction Notice: Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Correction Notice
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869616/ https://www.ncbi.nlm.nih.gov/pubmed/35224454 http://dx.doi.org/10.1097/HS9.0000000000000703

Ejemplares similares

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
por: Tettero, Jesse M., et al.
Publicado: (2021)

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
por: Hochhaus, A., et al.
Publicado: (2020)

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
por: Cross, Nicholas C. P., et al.
Publicado: (2023)

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2020)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
por: Bataller, Alex, et al.
Publicado: (2022)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
por: Steegmann, J L, et al.
Publicado: (2016)

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
por: Mrózek, Krzysztof, et al.
Publicado: (2023)

Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet
por: van der Velden, Vincent H. J., et al.
Publicado: (2021)

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group
por: Porwit, Anna, et al.
Publicado: (2022)

Effects of Intermittent Fasting on Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia: An Outcome of European LeukemiaNet Project
por: Yassin, Mohamed A., et al.
Publicado: (2021)

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response
por: Begna, K. H., et al.
Publicado: (2022)

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
por: Hochman, Michael J., et al.
Publicado: (2023)

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera
por: Tremblay, Douglas, et al.
Publicado: (2022)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia
por: Bill, Marius, et al.
Publicado: (2020)

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
por: Wille, Kai, et al.
Publicado: (2023)

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet
por: Itzykson, Raphael, et al.
Publicado: (2018)

Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project
por: Abdulla, Mohammad A. J., et al.
Publicado: (2021)

European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
por: Medeiros, B C, et al.
Publicado: (2014)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
por: Tiong, Ing S., et al.
Publicado: (2023)

Correction Notice: Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges? Summary of the EHA Guideline on Antifungal Prophylaxis in Adult Patients With Acute Myeloid Leukemia Treated With Novel-targeted Therapies
Publicado: (2022)

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
por: Patkar, Nikhil, et al.
Publicado: (2021)

A three-gene expression-based risk score can refine the European LeukemiaNet AML classification
por: Wilop, Stefan, et al.
Publicado: (2016)

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
por: Sargas, Claudia, et al.
Publicado: (2023)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Bill, Marius, et al.
Publicado: (2023)

NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
por: Li, Yonghong, et al.
Publicado: (2023)

Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
por: Roloff, Gregory W., et al.
Publicado: (2017)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Notices
Publicado: (2009)

Notice
Publicado: (2013)

Notice
por: Fitch, T. D.
Publicado: (1871)

Notices
Publicado: (1871)

Notices
Publicado: (1871)

Notices
Publicado: (1872)

Notices
Publicado: (1871)

Cannot write session to /tmp/vufind_sessions/sess_jk12rth6o8clqm05jj4e1ohu9i